Patients receiving systemic treatment with any immunosuppressive medication (other than steroids as described above).
Receipt of any anticancer medication in the 21 days prior to receiving the first dose of study medication
Current or prior use of immunosuppressive medication within 14 days prior to the first dose Additional Exclusion Criteria for Arm A
Use of immunosuppressive medication at the time of enrollment
Participants receiving systemic treatment with any immunosuppressive medication (other than steroids as described above)
Participant must not have current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).
Current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).
Patients receiving systemic treatment with any immunosuppressive medication, excepting the above
Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
Patients who are taking immunosuppressive medication
Treatment with systemic immunosuppressive medication;
Current or prior use of immunosuppressive medication within 28 days before the first study treatment
Prior medication:
Current or prior use of immunosuppressive medication within 7 days prior to study entry
Current or prior use of immunosuppressive medication within 14 days with some exceptions
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study treatment
Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment
Current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).
Patients receiving systemic treatment with any immunosuppressive medication.
Patients who are taking immunosuppressive medication
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI5083
Current use of immunosuppressive medication at study entry, with the following exceptions:
Current use of immunosuppressive medication at the time of study enrollment.
Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study
Current or prior use of immunosuppressive medication within 14 days with some exceptions.
Immunosuppression: Any immunosuppressive medication must be stopped ? 4 weeks prior to enrollment
Concurrent or prior use of immunosuppressive medication with 14 days
Subject use of immunosuppressive medication within 14 days before Cycle 1 Day 1.
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion:
Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of IP. The following are exceptions to this criterion:
Patients receiving systemic treatment with any immunosuppressive medication.
Prior medication:
Systemic immunosuppressive medication within 2 weeks prior to study drug
Current or prior use of immunosuppressive medication within 28 days before start of treatment.
Current or prior use of immunosuppressive medication within 14 days of first dose
Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment
Post-transplant exposure to any novel immunosuppressive medication (e.g., alemtuzumab) within 100 days prior to enrollment
Current or prior use of immunosuppressive medication within 14 days before the first dose of their assigned Investigational Product;
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI6383. )
Current or prior use of immunosuppressive medication within 14 days before the first dose of MEDI4736
Current use of immunosuppressive medication at the time of study enrollment.
Ongoing ? Grade 2 toxicities from previous cancer therapies unless specifically allowed in the Inclusion/Exclusion criteria. Use of immunosuppressive medication other than steroids within 28 days before the first dose of MEDI-551
Concurrent or prior use of immunosuppressive medication within 28 days;
Concurrent or prior use of immunosuppressive medication within 14 days
Use of immunosuppressive medication or systemic steroids within 7 days prior to first dose of MEDI3617
Subjects on concurrent anticoagulant, or immunosuppressive medication
Subjects on concurrent anticoagulant, or immunosuppressive medication
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study treatment
Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment
Exposure to any new immunosuppressive medication in the 4 weeks prior to enrollment
Patients with steroid refractory cGVHD cannot have prior exposure to any new immunosuppressive medication in the preceding 2 weeks prior to enrollment
Treatment with systemic immunosuppressive medication
